天域生物科技股份有限公司详式权益变动报告书 天域生物科技股份有限公司 上市公司名称： 天域生物科技股份有限公司 股票上市地点： 上海证券交易所 股票简称： 天域生物 股票代码： 603717 信息披露义务人 1： 罗卫国 上海市杨浦区国权北路 1688 弄湾谷科技园 C4 幢莱蒙 住所/通讯地址： B 座 202-203 室天域生物 信息披露义务人 2： 上海导云资产管理有限公司 住所/通讯地址： 上海市杨浦区国权北路 1688 弄 12 号 301-2 室 一致行动关系解除、原一致行动人表决权放弃、认购 股份变动性质 上市公司向特定对象发行的股票 签署日期：2025 年 8 月 26 日 天域生物科技股份有限公司详式权益变动报告书 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》《上市公司收购管理 办法》《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报 告书》《公开发行证券的公司信息披露内容与格式准则第 16 号——上市公司收 购报告书》及其他相关法律、法规和规范性文件编写本报告书。 二、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发 行证券的公司信息披露 ...

天域生物科技股份有限公司 关于实际控制人签署《 <一致行动协议> 之解除协议》 《表决权放弃协议》暨公司实际控制人发生变更 的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容及风险提示： ? 实际控制人变更的主要内容 是否发生变更 变更前姓名/名称 变更后姓名/名称 实际控制人 ?是 ?否 罗卫国、史东伟 罗卫国 □协议转让 □司法划转/拍卖 □定向增发 证券代码：603717 证券简称：天域生物 公告编号：2025-060 □破产重整引入重整投资人 □表决权委托 变更方式（可多选） □行政划转或者变更 □一致行动关系内部转让 ?一致行动协议签署/解除/变更 □要约收购 □间接收购 ?表决权放弃 □继承 ? 天域生物科技股份有限公司（以下简称"公司"或"天域生物"）实际控制人 罗卫国与史东伟于 2025 年 08 月 25 日签署了《 <一致行动协议> 之解除协议》 （以下简 称"《解除协议》"），双方一致行动关系于《解除协议》签署生效之日起终止。同日， 史东伟辞去公司总裁职务不再直接参与公司日常经营管理， ...

天域生物科技股份有限公司 上市公司名称：天域生物科技股份有限公司 股票上市地点：上海证券交易所 股票简称：天域生物 股票代码：603717 信息披露义务人：史东伟 住所/通讯地址：上海市杨浦区国权北路 1688 弄湾谷科技园 C4 幢莱蒙 B 座 股份变动性质：一致行动关系解除、表决权放弃 签署日期：2025 年 8 月 25 日 天域生物科技股份有限公司简式权益变动报告书 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》《上市公司收购管理办 法》 《公开发行证券的公司信息披露内容与格式准则第15号——权益变动报告书》 及其他相关法律、法规和规范性文件编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行 证券的公司信息披露内容与格式准则第15号——权益变动报告书》的规定，本报 告书已全面披露信息披露义务人在天域生物科技股份有限公司中拥有权益的股 份变动情况。 天域生物科技股份有限公司简式权益变动报告书 天域生物科技股份有限公司简式权益变 ...

Group 1 - The company raised a total of RMB 402.27 million through a private placement of 48.35 million shares at a price of RMB 8.32 per share, with a net amount of RMB 393.87 million after deducting issuance costs [1][3] - As of June 30, 2025, the balance of the raised funds in the special account was RMB 187,615.74, with an additional RMB 61.69 million remaining unutilized, accounting for 15.33% of the total raised funds [2][3] - The company plans to use the remaining funds according to the construction progress of the Tianchang Longgang Red Culture Tourism Scenic Area project, which is expected to be completed by 2025 [2][3] Group 2 - The company has approved the temporary use of idle raised funds for working capital, with amounts of RMB 130 million, RMB 220 million, and RMB 160 million used in different periods, all of which have been returned to the special account [1][2] - The internal rate of return for the Tianchang Longgang Red Culture Tourism Scenic Area project has been adjusted from 25% to 17% due to project delays, impacting the expected cumulative gross profit [2][3] - The company has confirmed that the actual use of raised funds aligns with the disclosures made in annual reports and other information disclosure documents, with no discrepancies found [2][3]

Group 1 - The company has established a three-year shareholder return plan for 2025-2027 to enhance transparency and operability in profit distribution policies [1][2] - The plan emphasizes sustainable development and considers factors such as operational performance, future development goals, and shareholder expectations [1][2] - The company aims to implement a stable and continuous profit distribution policy, prioritizing cash dividends over stock dividends [2][3] Group 2 - The company will distribute at least 10% of its distributable profits as cash dividends annually, provided it meets certain conditions [2][3] - The cash dividend proportion varies based on the company's development stage and capital expenditure needs, with a minimum of 80% for mature stages without major expenditures [3][4] - The board of directors is responsible for proposing profit distribution plans, which must be approved by the shareholders' meeting, ensuring independent directors and minority shareholders' opinions are considered [3][4][5] Group 3 - In cases where cash dividends are not proposed, the board must provide specific reasons and disclose the intended use of retained earnings [4][5] - The company will utilize online voting for shareholders during meetings to facilitate communication, especially with minority shareholders [4][5] - Any adjustments to the profit distribution policy due to significant changes in the operating environment must be proposed by the board and approved by the shareholders' meeting [4][5]

Core Viewpoint - Tianyu Biotechnology Co., Ltd. has announced that it has not faced any penalties from regulatory authorities or exchanges in the past five years, while also detailing the measures taken in response to previous regulatory actions against its controlling shareholder and a subsidiary [1][2][4]. Recent Regulatory Actions and Rectification - The company’s controlling shareholder, Luo Weiguo, received a public reprimand from the Shanghai Stock Exchange for failing to disclose changes in shareholding timely, which resulted from a dilution of shares due to a non-public stock issuance [2]. - The company was subject to administrative regulatory measures by the China Securities Regulatory Commission (CSRC) for inadequate impairment provisions related to a long-term equity investment, which violated accounting standards [2][4]. - The company has established a special rectification working group to address the issues, ensuring compliance with accounting standards and improving governance structures [3][4]. - The former financial director, Sun Weidong, received a regulatory warning for inaccuracies in financial disclosures and has since resigned from his position [4]. - The company has confirmed that its current directors and senior management have not faced any administrative penalties from the CSRC in the last three years [5].

证券代码：603717 证券简称：天域生物 天域生物科技股份有限公司 募集资金使用可行性分析报告 二〇二五年八月 本可行性分析报告中如无特别说明，相关用语具有与《天域生物科技股份有 限公司 2025 年度向特定对象发行 A 股股票预案》中相同的含义。公司拟申请向 特定对象发行股票，现将本次发行募集资金投资项目可行性分析说明如下： 一、本次向特定对象发行股票募集资金的使用计划 本次向特定对象发行 A 股股票数量原拟定为不超过 80,417,610 股（含本数）， 募集资金总额原拟定为不超过人民币 52,673.53 万元（含本数），考虑到公司拟 继续使用不超过人民币 6,150 万元的闲置前次募集资金暂时补充公司流动资金， 扣除该部分流动资金影响后，本次向特定对象发行 A 股股票数量确定为不超过 并以中国证监会关于本次发行的注册批复文件为准。本次发行所募集资金在扣除 相关发行费用后将全部用于补充流动资金和偿还债务。 本次发行募集的资金将全部用于补充流动资金及偿还债务，有利于公司积极 健康的发展，进而提高上市公司的整体盈利能力。 截至 2025 年 3 月 31 日，公司资产负债率为 75.91%，超过同行业上市 ...

证券代码：603717 证券简称：天域生物 公告编号：2025-063 公司本次向特定对象发行 A 股股票预案披露事项不代表审批机关对本次向 特定对象发行 A 股股票相关事项的实质性判断、确认或批准，本次向特定对象 发行 A 股股票相关事项的生效和完成尚需公司股东大会审议通过、上海证券交 易所审核通过及中国证监会作出同意注册决定后方可实施。敬请广大投资者注意 投资风险。 特此公告。 天域生物科技股份有限公司董事会 天域生物科技股份有限公司（以下简称"公司"）于 2025 年 08 月 25 日分 别召开第四届董事会第四十三次会议、第四届监事会第三十六次会议，审议通过 了《关于 <公司 a="A" ensp="ensp" 年度向特定对象发行="年度向特定对象发行" 股股票预案="股股票预 案"> 的议案》及其他相关议 案。具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）上披露 的《天域生物科技股份有限公司 2025 年度向特定对象发行 A 股股票预案》，敬 请广大投资者注意查阅。 天域生物科技股份有限公司 关于 2025 年度向特定对象发行 A 股股票预案 披露的提示性公告 本公司董事 ...

Group 1 - The company plans to issue shares to a specific group, aiming to enhance its capital structure and improve financial stability [3][4][26] - The issuance is driven by high debt levels and the need for liquidity, with the company's debt-to-asset ratio reaching 75.91% as of March 31, 2025 [4][5][6] - The actual controller's confidence in the company's future is reflected in the full subscription of the shares by the controlling entity, which is expected to stabilize control and support future growth [3][7][26] Group 2 - The funds raised will be used to supplement working capital and repay debts, which is crucial for the company's operational continuity and financial health [4][21][24] - The issuance will lead to an increase in total shares and net assets, potentially diluting earnings per share in the short term, with projections indicating a basic earnings per share of -0.37 before and after the issuance [16][18][21] - The company has committed to measures to mitigate the impact of dilution on immediate returns, ensuring that shareholder interests are protected [23][25][26] Group 3 - The issuance process adheres to relevant regulations, including the Securities Law and the Management Measures for the Issuance of Securities by Listed Companies [10][11][12] - The pricing of the shares is set at 6.55 yuan per share, which is 80% of the average trading price over the previous 20 trading days [9][10] - The company will ensure that the funds are managed and utilized according to established regulations, enhancing transparency and efficiency in fund usage [24][26]

Group 1 - The company Tianyu Bio-Technology Co., Ltd. plans to issue shares to a specific group, with the aim of raising funds to supplement working capital and repay debts [2][11][14] - The issuance will involve a maximum of 71,028,297 shares, which is capped at 30% of the company's total share capital prior to the issuance [13][15] - The share price is set at 6.55 RMB per share, which is not less than 80% of the average trading price over the 20 trading days prior to the pricing benchmark date [12][29] Group 2 - The issuance is characterized as a related party transaction, as the shares will be fully subscribed by Shanghai Daoyun Asset Management Co., Ltd., controlled by the company's actual controller, Luo Weiguo [10][15] - The company has a high debt ratio, with figures of 59.13%, 74.51%, 77.96%, and 75.91% at the end of the reporting periods, indicating significant financial pressure [10] - The funds raised will be used entirely for operational needs and debt repayment, which is expected to optimize the company's capital structure and enhance its sustainability [11][14] Group 3 - The company aims to enhance its control stability through this issuance, as the actual controller's stake will increase, reflecting confidence in the company's future [10][11] - The issuance is not expected to change the company's control structure, as the actual controller will maintain a significant voting power post-issuance [15] - The company has established a profit distribution policy to ensure transparency and stability in shareholder returns, aligning with regulatory guidelines [4][10]